Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3134318rdf:typepubmed:Citationlld:pubmed
pubmed-article:3134318lifeskim:mentionsumls-concept:C0038404lld:lifeskim
pubmed-article:3134318lifeskim:mentionsumls-concept:C0008809lld:lifeskim
pubmed-article:3134318lifeskim:mentionsumls-concept:C0014310lld:lifeskim
pubmed-article:3134318lifeskim:mentionsumls-concept:C0028365lld:lifeskim
pubmed-article:3134318lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:3134318lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:3134318lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:3134318lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:3134318pubmed:issue5lld:pubmed
pubmed-article:3134318pubmed:dateCreated1988-8-17lld:pubmed
pubmed-article:3134318pubmed:abstractTextThe response to three quinolones of a clinical isolate of Streptococcus faecalis was studied by continuous turbidimetric monitoring, by viable counting, and in an in-vitro model of the treatment of bacterial cystitis. Dense populations (c. 8 x 10(6) cfu/ml) responded to ciprofloxacin, norfloxacin and enoxacin at concentrations below the conventionally determined MIC, but variants, shown to exhibit decreased susceptibility, emerged during overnight incubation. The variants were cross-resistant to each of the three quinolones, but the resistance was lost on subculture in drug-free broth. At a concentration of ten-fold MIC, ciprofloxacin was more bactericidal than norfloxacin or enoxacin. In experiments in the bladder model, doses of ciprofloxacin achieving a peak concentration of 10, 50 or 250 mg/l suppressed bacterial growth for 20 h or more. The doses of norfloxacin or enoxacin required to achieve a comparable effect were higher than those of ciprofloxacin. A reduction in susceptibility, as judged by comparative disc testing, occurred after two cycles of exposure to norfloxacin or enoxacin in experiments in which the peak concentration achieved was 50 mg/l, but not when the peak was 250 mg/l. Reduced susceptibility to ciprofloxacin developed only in experiments in which a lower peak concentration of 10 mg/l was achieved.lld:pubmed
pubmed-article:3134318pubmed:languageenglld:pubmed
pubmed-article:3134318pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3134318pubmed:citationSubsetIMlld:pubmed
pubmed-article:3134318pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3134318pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3134318pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3134318pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3134318pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3134318pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3134318pubmed:statusMEDLINElld:pubmed
pubmed-article:3134318pubmed:monthMaylld:pubmed
pubmed-article:3134318pubmed:issn0305-7453lld:pubmed
pubmed-article:3134318pubmed:authorpubmed-author:GreenwoodDDlld:pubmed
pubmed-article:3134318pubmed:authorpubmed-author:MuranakaKKlld:pubmed
pubmed-article:3134318pubmed:issnTypePrintlld:pubmed
pubmed-article:3134318pubmed:volume21lld:pubmed
pubmed-article:3134318pubmed:ownerNLMlld:pubmed
pubmed-article:3134318pubmed:authorsCompleteYlld:pubmed
pubmed-article:3134318pubmed:pagination545-54lld:pubmed
pubmed-article:3134318pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3134318pubmed:meshHeadingpubmed-meshheading:3134318-...lld:pubmed
pubmed-article:3134318pubmed:meshHeadingpubmed-meshheading:3134318-...lld:pubmed
pubmed-article:3134318pubmed:meshHeadingpubmed-meshheading:3134318-...lld:pubmed
pubmed-article:3134318pubmed:meshHeadingpubmed-meshheading:3134318-...lld:pubmed
pubmed-article:3134318pubmed:meshHeadingpubmed-meshheading:3134318-...lld:pubmed
pubmed-article:3134318pubmed:meshHeadingpubmed-meshheading:3134318-...lld:pubmed
pubmed-article:3134318pubmed:meshHeadingpubmed-meshheading:3134318-...lld:pubmed
pubmed-article:3134318pubmed:meshHeadingpubmed-meshheading:3134318-...lld:pubmed
pubmed-article:3134318pubmed:meshHeadingpubmed-meshheading:3134318-...lld:pubmed
pubmed-article:3134318pubmed:meshHeadingpubmed-meshheading:3134318-...lld:pubmed
pubmed-article:3134318pubmed:meshHeadingpubmed-meshheading:3134318-...lld:pubmed
pubmed-article:3134318pubmed:year1988lld:pubmed
pubmed-article:3134318pubmed:articleTitleThe response of Streptococcus faecalis to ciprofloxacin, norfloxacin and enoxacin.lld:pubmed
pubmed-article:3134318pubmed:affiliationDepartment of Microbiology, University Hospital, Queen's Medical Centre, Nottingham, UK.lld:pubmed
pubmed-article:3134318pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3134318lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3134318lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3134318lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3134318lld:pubmed